T-ALL

ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING

Retrieved on: 
월요일, 12월 12, 2022
BCMA, Daratumumab, Mouse, Oncology, T-cell acute lymphoblastic leukemia, MD, Infection, IND, Poster, Doctor of Philosophy, Multiple myeloma, CD38, Society, Patient, ISB, Treatment, Trace fossil classification, Research, HIV disease progression rates, Medicine, RRMM, Superior, MM, Antibody, Health, AML, Clinical trial, T-ALL, Relapse, Multimedia, Acute myeloid leukemia, CTN, Half-life, CRS, ASH, Risk, Vaccine, Pharmaceutical industry, Online shopping, NEW YORK, B cell

NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, shared data during an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition supporting the advancement of its first-in-class TREAT™1 trispecific antibody, ISB 2001, to a first-in-human clinical trial. Both IND and CTN filings are planned during the first quarter of calendar year 2023 and preparations for a Phase 1 clinical trial in relapsed/refractory multiple myeloma (RRMM) are under way.

Key Points: 
  • Dual targeting with ISB 2001 may overcome escape mechanisms associated with BCMA and CD38 therapeutic antibodies, including approved T cell engagers.
  • In addition to the oral presentation on trispecific antibody ISB 2001 described above, Ichnos was selected for three poster presentations of data on other pipeline assets:
    1.
  • More information about the three oncology assets highlighted at the meeting, and the rest of Ichnos' pipeline can be found at this link .
  • With its patented BEATtechnology platform and pioneering teams, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
월요일, 11월 14, 2022
BRM, Clinical trial, Brain, T-ALL, MYC, Thrombocytopenia, Monocyte, CLL, Safety, Security (finance), Anemia, Research and development, BTK, Prelude, R, Administration, Constipation, Drug resistance, CDK9, SMARCA4, Biotechnology, G&A, Research, Vomiting, NHL, COVID-19, Public expenditure, Incidence, Uveal melanoma, Large-cell lung carcinoma, FDA, Pharmacology, Sarcoma, BH3, CDK, Mesothelioma, Lymphoid neoplasms with plasmablastic differentiation, Hematological Cancer Research Investment and Education Act, Cancer, Pharmacokinetics, IND, MCL1, Fatigue, CD14, Glioma, Breast cancer, PRMT5, Human, SMARCA2, Risk, Nausea, Head, Patient, Pharmaceutical industry, Medical device

WILMINGTON, Del., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.

Key Points: 
  • I believe these programs offer the best chance to improve patient outcomes and I share our investigators excitement in our highly differentiated molecules.
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2022, were $224.0 million.
  • Prelude anticipates that its existing cash, cash equivalents and marketable securities will be sufficient to fund Preludes operations into the fourth quarter of 2024.
  • We expect our research and development expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
월요일, 9월 12, 2022
People, Adenoid cystic carcinoma, Safety, Quality of life, Patient, Physician, Oncology, Abdominal wall, Nasdaq, Multiple myeloma, PR, ESMO, Aggressive fibromatosis, Treatment, ACC, Head, Organ dysfunction, European Society for Medical Oncology, RECIST, Pivotal, Plantar fibromatosis, FDA, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, MM, AYLA, DOR, Royal Marsden Hospital, QOL, Progression-free survival, GLOBE, Congress, Therapy, Incidence, Doctor of Philosophy, MRI, Cancer, ORR, T-ALL, PFS, Chronic pain, Recurrence, Pharmaceutical industry, Medical imaging, Public relations, Notch, Part

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update

Retrieved on: 
목요일, 7월 28, 2022
Time, Inflammation, Skin, Capsule, Psoriasis, MHRA, Degenerative disease, Institute of Cancer Research, AIM, Biomarker, CRO, Toxicology, CTA, Patent, GMP, Safety, COVID-19, JAK1, Cancer, Q&A, Clinical trial, Company, Patient, T-ALL, The Institute, GlaxoSmithKline, Medicines and Healthcare products Regulatory Agency, TYK2, Survival, CHEK1, Autoimmune disease, Pharmaceutical industry, Vaccine, IMC

Sareum also provides a broader update on operational activities and pipeline progress.

Key Points: 
  • Sareum also provides a broader update on operational activities and pipeline progress.
  • Preclinical development activities required to apply for the CTA have been successfully concluded and, consistent with the Companys clinical development plan, an application for a CTA has now been filed.
  • TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis.
  • Sareum, working alongside a specialist contract research organisation (CRO), has designed a Phase 1a/b clinical trial with SDC-1801 in healthy subjects and psoriasis patients.

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
목요일, 6월 2, 2022
MM, Adenoid cystic carcinoma, Therapy, Plantar fibromatosis, T-ALL, FDA, Patient, Multiple myeloma, Pivotal, ACC, Novartis, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, Cancer, Pharmaceutical industry, Notch

A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.

Key Points: 
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations.

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

Retrieved on: 
목요일, 5월 12, 2022
DL2, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, CAR, Cancer, Risk, Lymphoid leukemia, Toxic epidermal necrolysis, IIT, CD7, NHL, HVG, SAN, NK, Form 20-F, Acute lymphoblastic leukemia, BCMA, Non-Hodgkin lymphoma, CT, Degenerative disease, 2021 Essex County Council election, Patient, Bone marrow, Gene editing, Cytokine release syndrome, HLA, Efficiency, Lymphatic system, First grade, European Hematology Association, Congress, ASCO, ALL, LinkedIn, CD19, Security (finance), Multiple myeloma, B-ALL, Annual report, NASDAQ, RRMM, Graft-versus-host disease, Industry, SMART, Safety, CRS, T-ALL, Lymphocyte, Pharmaceutical industry, Vaccine, Medical imaging, Fashion, Graceling, Indian Institutes of Technology

"The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.

Key Points: 
  • "The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.
  • The CD19/CD7 dual-directed CAR-T therapy GC502 is our second allogeneic candidate on our TruUCAR platform, demonstrating the potential wide applicability of the TruUCAR design."
  • Gracell will present the early results of the first-in-human phase 1 IIT in China evaluating the safety and tolerability of GC012F in B-NHL patients.
  • Three patients who had received a median of two prior lines of therapy were enrolled, all of which presented with bulky disease.

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

Retrieved on: 
금요일, 4월 8, 2022
Online, B-ALL, LinkedIn, PALO, Form 20-F, NASDAQ, Private Securities Litigation Reform Act, DL2, Degenerative disease, Trial of the century, Lymphocyte, SMART, Cytokine release syndrome, Annual report, CRS, Bone marrow, CAR, AACR, Risk, American Association, Patient, Holm–Bonferroni method, Cancer, HVG, U.S. Securities and Exchange Commission, CD7, ALL, Lymphoid leukemia, Association, American Association for Cancer Research, Gene editing, Industry, Graft-versus-host disease, CD19, HLA, Acute lymphoblastic leukemia, IIT, Lymphatic system, T-ALL, Security (finance), Pharmaceutical industry, Vaccine, Graceling

PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.

Key Points: 
  • Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.
  • "We are very excited to present our data on GC502 at this year's AACR annual meeting.
  • CD19 is a validated target in the treatment of r/r B-ALL," said Dr. Martina Sersch, Chief Medical Officer of Gracell.
  • The early results show the potential of GC502 and warrant further evaluation in the ongoing clinical investigator-initiated-trial (IIT).

Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL

Retrieved on: 
화요일, 3월 15, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, DOR, ODD, TRAC, T-cell acute lymphoblastic leukemia, Technology, Associate, Patient, Prescription Drug User Fee Act, NK, FDA, T-ALL, Orphan Drug Act of 1983, Acute lymphoblastic leukemia, Risk, Lymphatic system, Safety, Acute leukemia, Oncology, George Washington University School of Medicine & Health Sciences, Cancer, Infection, Food, ORR, NCT, Population, Graft-versus-host disease, Division, CD7, AML, PDUFA, LBL, CRISPR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Marketing, Pharmaceutical industry, Vaccine, WU-CART-007, Wugen, WU-CART-007, WUGEN

Additionally, Wugen announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to WU-CART-007 for the treatment of acute lymphoblastic leukemia.

Key Points: 
  • Additionally, Wugen announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to WU-CART-007 for the treatment of acute lymphoblastic leukemia.
  • We look forward to advancing WU-CART-007, which has the potential to transform the care paradigm for these patients.
  • The Phase 1/2 trial is a first-in-human, multi-site, global, open-label study of WU-CART-007 to evaluate its safety and clinical efficacy in patients with R/R T-ALL/LBL.
  • WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
수요일, 3월 9, 2022
TNBC, Multiple myeloma, Plantar fibromatosis, Novartis, Patient, Therapy, FDA, T-ALL, Cancer, Pivotal, ACC, MM, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, Adenoid cystic carcinoma, Pharmaceutical industry, Notch

A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.

Key Points: 
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • For more information, visit www.ayalapharma.com .

Wugen to Present Virtually at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

Retrieved on: 
수요일, 3월 9, 2022
Banking, Research, Other Health, General Health, Professional Services, Pharmaceutical, Oncology, Science, Other Professional Services, Biotechnology, Finance, Health, Other Science, Acute leukemia, T-cell acute lymphoblastic leukemia, T-ALL, AML, Conference, NK, Infection, LBL, Vaccine

Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m.

Key Points: 
  • Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m.
  • The presentation will be available to registered conference attendees.
  • Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection.
  • Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).